Novartis Reports Publication of P-IIIb LIBERTY study’s Results of Aimovig (erenumab) in The Lancet

 Novartis Reports Publication of P-IIIb LIBERTY study’s Results of Aimovig (erenumab) in The Lancet

Novartis Reports Publication of P-IIIb LIBERTY study’s Results of Aimovig (erenumab) in The Lancet

Shots:

  • The P-IIIb Liberty study involves assessing of Aimovig (140 mg) vs PBO @12 wks. in patients with episodic migraine (4 to 14 migraine days/month)
  • P-IIIb LIBERTY study results: reduction in migrane days 50% @1EP (30% vs 14%); reduction in migrane days 75% @2EP (12% vs 4%); migrane free patients 6%; MMD (1.8 vs 0.2) reductions in the no. of days/month using acute migraine-specific medication (1.3 vs 0.5)
  • Aimovig is a novel approved CGRP-targeted therapy for migrane by the US and EU including Canada, Australia, Switzerland, the UAE and Singapore

Click here to read full press release/ article | Ref: Novartis | Image:  WSJ

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post